The Effect of Raloxifene on the Incidence of Ovarian Cancer in Postmenopausal Women
- 31 May 2002
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 85 (2) , 388-390
- https://doi.org/10.1006/gyno.2001.6578
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US WomenJAMA, 2001
- Long-term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal WomenArchives of internal medicine (1960), 2000
- A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancerJournal of Clinical Epidemiology, 2000
- The reversible effects of raloxifene on luteinizing hormone levels and ovarian morphology in miceReproductive Toxicology, 2000
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999
- The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal WomenJAMA, 1999
- Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysisPublished by Wolters Kluwer Health ,1998
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Hormone replacement therapy and endometrial cancer risk: A meta-analysisObstetrics & Gynecology, 1995